source
- FDA finds Replimune's melanoma data package uninterpretable, foreshadows tough advisory committee reviewThe FDA has deemed the single-arm mid-stage study submitted by Replimune for its oncolytic immunotherapy RP1 as not interpretable, raising concerns ahead of an upcoming advisory committee meeting.…
- Eli Lilly climbs to top of Norstella’s Pipeline-to-Patient Productivity Index, beating 24 peersEli Lilly has risen to the top of Norstella’s inaugural Pipeline-to-Patient Productivity Index, a new benchmark that rates large global biopharma firms on research productivity, market access and c…